Medicine and Dentistry
Programmed Death-Ligand 1
83%
Ipilimumab
77%
Pembrolizumab
67%
Lung Cancer
66%
Metastatic Melanoma
66%
Nivolumab
65%
Melanoma
54%
Overall Survival
46%
Immune Checkpoint Inhibitor
44%
Adverse Event
41%
Mesothelioma
41%
Physical Activity
41%
Clinical Trial
41%
Lung
38%
Quality of Life
36%
Progression Free Survival
35%
Small Cell Lung Cancer
33%
Circulating Tumor Cell
33%
Cachexia
33%
Procalcitonin
33%
Dabrafenib
33%
T Cell
33%
Infection
33%
Skin Carcinoma
33%
Health Outcomes
33%
Placebo
33%
Cohort Analysis
33%
Immunotherapy
33%
Trametinib
33%
Cytotoxic T Lymphocyte Antigen 4 Antibody
33%
Neoplasm
31%
Hazard Ratio
26%
Diseases
25%
Pleura Mesothelioma
25%
Skeletal Muscle
25%
Immune-Related Adverse Events
22%
Biological Marker
22%
Non Small Cell Lung Cancer
19%
Electrocorticography
17%
Cancer
16%
Oncology
16%
Cemiplimab
13%
Smoking
12%
Hand Grip
11%
Cancer Immunology
11%
Prospective Cohort Study
11%
Regulatory T Cell
11%
Clinical Decision Making
11%
Immune Checkpoint Blockade
11%
Lymphocyte
11%
Pharmacology, Toxicology and Pharmaceutical Science
Small Cell Lung Cancer
66%
Metastatic Melanoma
66%
Neoplasm
66%
Melanoma
54%
Immune Checkpoint Inhibitor
50%
Ipilimumab
50%
Clinical Trial
48%
Nivolumab
42%
Lung Cancer
41%
Pembrolizumab
39%
Adverse Event
36%
Progression Free Survival
35%
Cytotoxic T Lymphocyte Antigen 4 Antibody
33%
Procalcitonin
33%
Lorlatinib
33%
Dabrafenib
33%
Anamorelin
33%
Skin Carcinoma
33%
Biological Marker
33%
Infection
33%
Cohort Study
33%
Trametinib
33%
Placebo
33%
Mesothelioma
33%
Cachexia
33%
Immunotherapy
33%
Overall Survival
31%
Malignant Neoplasm
29%
Diseases
21%
Prospective Cohort Study
16%
Prevalence
16%
Non Small Cell Lung Cancer
16%
Flow Cytometry
16%
Side Effect
16%
Cemiplimab
13%
Epithelial Cell Adhesion Molecule
9%
Pneumonia
9%
Cytotoxic Chemotherapy
8%
C Reactive Protein
8%
Sepsis
8%
Ghrelin Receptor
8%
Receptor Agonist
8%
Inflammation
8%
Advanced Cancer
8%
Brain Metastasis
8%
Protein Tyrosine Kinase Inhibitor
8%
Neutropenia
8%
Retrospective Study
6%
Observational Study
6%
Autoimmune Disease
6%
Immunology and Microbiology
Programmed Death-Ligand 1
100%
Immunotherapy
66%
Circulating Tumor Cell
66%
Immunity
55%
Cell Subpopulation
33%
T Cell
33%
Human Leukocyte Antigen
33%
Nivolumab
22%
Epithelial Cell Adhesion Molecule
16%
Overall Survival
11%
Clinical Decision Making
11%
Peripheral Blood Lymphocyte
11%
Regulatory T Cell
11%
Pembrolizumab
11%
Immune Checkpoint Blockade
11%
Ipilimumab
11%
Cancer Immunology
11%
Prevalence
10%
Progression Free Survival
8%
Homozygosity
8%
Tumor Cell
6%
Antineoplastic Activity
5%